Cancer Council Victoria | Victorian Cancer Trials Link

# REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2

## Clinical summary

This study is assessing how safe and effective the drugs ruxolitinib and eltrombopag are in people with relapsed or refractory aplastic anaemia or post graft function following allogenic stem cell transplantation (ASCT).
The study will consist of screening and enrolment (up to 28 days), treatment (12 weeks), and follow up (up to 9 months post enrolment). Therefore, the maximum time on study for a single patient will be a maximum of 12 months.
Upon enrolment, participants in the intervention arm will commence treatment with Ruxolitinib and Eltrombopag. Dose adjustments may be required based on lack of efficacy or thrombocytopenia. 

## Conditions

This trial is treating patients with poor graft function or relapsed or refractor aplastic anaemia

**Trial Acronym**
RESELECT2

**Trial Identifiers**
NCT06607367
2024.231

**Cancer**
Aplastic Anaemia

**Age:** 18+
**Phase:** I/II

**For full trial details, visit trials.cancervic.org.au/details/vctl_nct06607367**